Renal Sympathetic Denervation by CT-Guided Ethanol Injection: A Phase II Pilot Trial of a Novel Technique

CardioVascular and Interventional Radiology

Volumn 39, Issue 2, 2016, Pages 251-260

  Ricke, J ^a,b   Seidensticker, M ^a,b   Becker, S ^a   Schiefer, J ^a   Adamchic, I ^a   Lohfink, K ^a   Kandulski, M ^a   Heller, A ^a   Mertens, P R ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Deutsche Akademie für Mikrotherapie International School of Image Guided Interventions   (Germany)

Author keywords

CT guided ablation; Sympathetic nerves; Therapy resistant arterial hypertension; Vasotonus

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALCOHOL; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPYRONE; DIURETIC AGENT; PARACETAMOL; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; KIDNEY DENERVATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; OPEN STUDY; PAIN; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; CLINICAL TRIAL; HYPERTENSION; INJECTION; INNERVATION; INTERVENTIONAL RADIOLOGY; KIDNEY; KIDNEY FUNCTION TEST; MIDDLE AGED; PROCEDURES; SYMPATHECTOMY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; ETHANOL; FEMALE; HUMANS; HYPERTENSION; INJECTIONS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PATIENT SAFETY; PILOT PROJECTS; RADIOGRAPHY, INTERVENTIONAL; SYMPATHECTOMY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84957843588     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-015-1261-6     Document Type: Article

References (32)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global Burden of disease study 2010. Lancet. 2012;380:2224–60.
2. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363–9.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52.
4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.
5. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076–80.
6. Norvell JE. The aorticorenal ganglion and its role in renal innervation. J Comp Neurol. 1968;133:101–11.
7. Newcombe CP, Shucksmith HS, Suffern WS. Sympathectomy for hypertension; follow-up of 212 patients. Br Med J. 1959;1:142–4.
8. Esler M, Jennings G, Korner P, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988;11:3–20.
9. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.
10. Catheter-based renal sympathetic denervation for resistant hypertension. durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.
11. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–9.
12. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.
13. Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385:1957–65.
14. Jang SH, Ahn SH, Park SM, Kim SH, Lee KH, Lee ZI. Alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle to treat ankle spasticity in patients with hemiplegic stroke. Arch Phys Med Rehabil. 2004;85:506–8.
15. Rogits B, Jungnickel K, Lowenthal D, et al. Prospective Evaluation of the radiologist’s hand dose in CT-guided interventions. Rofo. 2013;185:1081–8.
16. Kambadakone A, Thabet A, Gervais DA, Mueller PR, Arellano RS. CT-guided celiac plexus neurolysis: a review of anatomy, indications, technique, and tips for successful treatment. Radiographics. 2011;31:1599–621.
17. Noble M, Gress FG. Techniques and results of neurolysis for chronic pancreatitis and pancreatic cancer pain. Curr Gastroenterol Rep. 2006;8:99–103.
18. Lee JM. CT-guided celiac plexus block for intractable abdominal pain. J Korean Med Sci. 2000;15:173–8.
19. Gress F, Schmitt C, Sherman S, Ikenberry S, Lehman G. A prospective randomized comparison of endoscopic ultrasound- and computed tomography-guided celiac plexus block for managing chronic pancreatitis pain. Am J Gastroenterol. 1999;94:900–5.
20. Fujita Y. CT-guided neurolytic splanchnic nerve block with alcohol. Pain. 1993;55:363–6.
21. Buy JN, Moss AA, Singler RC. CT guided celiac plexus and splanchnic nerve neurolysis. J Comput Assist Tomogr. 1982;6:315–9.
22. Streitparth F, Walter A, Stolzenburg N, et al. MR-guided periarterial ethanol injection for renal sympathetic denervation: a feasibility study in pigs. Cardiovasc Interv Radiol. 2013;36:791–6.
23. Streitparth F, Gebauer B, Nickel P, et al. Percutaneous computer tomography-guided ethanol sympathicolysis for the treatment of resistant arterial hypertension. Cardiovasc Interv Radiol. 2014;37:513–8.
24. Firouznia K, Hosseininasab SJ, Amanpour S, Haj-Mirzaian A, Miri R, Muhammadnejad A, Muhammadnejad S, Jalali AH, Ahmadi F, Rokni-Yazdi H. Renal sympathetic denervation by CT-scan-guided periarterial ethanol injection in sheep. Cardiovasc Interv Radiol. 2015;38(4):977–84.
25. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380:778.
26. Kaltenbach B, Id D, Franke JC, et al. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60:2694–5.
27. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35:528–35.
28. Gelczer RK, Charboneau JW, Hussain S, Brown DL. Complications of percutaneous ethanol ablation. J Ultrasound Med. 1998;17:531–3.
29. May O. The functional and histological effects of intraneural and intraganglionic injections of alcohol. Br Med J. 1912;2:465–70.
30. Xu RH, Gao W, Wang C, et al. Systematic evaluation of percutaneous radiofrequency ablation versus percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: a meta-analysis. Eur J Med Res. 2014;19:39.
31. Wang S, Zhuang L, Meng Z. Hepatocellular carcinoma more than 3 cm in diameter: a systematic review of transcatheter arterial chemoembolization plus percutaneous ethanol injection versus transcatheter arterial chemoembolization alone. ISRN Gastroenterol. 2013;2013:526024.
32. Fischell TA, Vega F, Raju N, et al. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model. EuroIntervention. 2013;9:140–7.